1. Home
  2. IVVD

as of 03-23-2026 3:36pm EST

$1.49
+$0.11
+7.61%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Founded: 2020 Country:
United States
United States
Employees: N/A City: NEW HAVEN
Market Cap: 437.1M IPO Year: 2021
Target Price: $8.75 AVG Volume (30 days): 2.0M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.30 EPS Growth: 79.02
52 Week Low/High: $0.46 - $3.07 Next Earning Date: 03-05-2026
Revenue: $53,426,000 Revenue Growth: 110.47%
Revenue Growth (this year): 143.48% Revenue Growth (next year): 25.40%
P/E Ratio: -4.60 Index: N/A
Free Cash Flow: -58290000.0 FCF Growth: N/A

AI-Powered IVVD Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 76.47%
76.47%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Invivyd Inc. (IVVD)

Green Julie

Chief Human Resources Officer

Sell
IVVD Feb 18, 2026

Avg Cost/Share

$1.58

Shares

20,964

Total Value

$33,077.00

Owned After

107,717

SEC Form 4

Andersen Jill

Chief Legal Officer, Secretary

Sell
IVVD Feb 18, 2026

Avg Cost/Share

$1.58

Shares

34,939

Total Value

$55,126.75

Owned After

181,736

SEC Form 4

Duke William E.

Chief Financial Officer

Sell
IVVD Feb 18, 2026

Avg Cost/Share

$1.58

Shares

20,964

Total Value

$33,077.00

Owned After

107,717

SEC Form 4

Lee Timothy Edward

Chief Commercial Officer

Sell
IVVD Feb 18, 2026

Avg Cost/Share

$1.58

Shares

20,964

Total Value

$33,077.00

Owned After

117,717

SEC Form 4

Allen Robert D. III

Chief Scientific Officer

Sell
IVVD Feb 18, 2026

Avg Cost/Share

$1.58

Shares

19,392

Total Value

$30,596.70

Owned After

114,487

SEC Form 4

Green Julie

Chief Human Resources Officer

Sell
IVVD Feb 17, 2026

Avg Cost/Share

$1.54

Shares

19,663

Total Value

$30,273.15

Owned After

107,717

SEC Form 4

Andersen Jill

Chief Legal Officer, Secretary

Sell
IVVD Feb 17, 2026

Avg Cost/Share

$1.54

Shares

32,771

Total Value

$50,454.23

Owned After

181,736

SEC Form 4

Duke William E.

Chief Financial Officer

Sell
IVVD Feb 17, 2026

Avg Cost/Share

$1.54

Shares

19,663

Total Value

$30,273.15

Owned After

107,717

SEC Form 4

Lee Timothy Edward

Chief Commercial Officer

Sell
IVVD Feb 17, 2026

Avg Cost/Share

$1.54

Shares

19,663

Total Value

$30,273.15

Owned After

117,717

SEC Form 4

Allen Robert D. III

Chief Scientific Officer

Sell
IVVD Feb 17, 2026

Avg Cost/Share

$1.54

Shares

18,189

Total Value

$28,003.78

Owned After

114,487

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2025
Q4

Q4 2025 Earnings

8-K SELL

Mar 5, 2026 · 100% conf.

AI Prediction SELL

1D

-2.20%

$1.62

Act: +3.16%

5D

-14.98%

$1.41

20D

-4.18%

$1.59

Price: $1.66 Prob +5D: 0% AUC: 1.000
0001193125-26-092528

8-K

false 0001832038 0001832038 2026-03-05 2026-03-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 5, 2026

Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter)

Delaware

001-40703

85-1403134

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

209 Church Street New Haven, CT

06510

(Address of Principal Executive Offices)

(Zip Code) Registrant’s telephone number, including area code: (781) 819-0080 Not applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

IVVD

The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On March 5, 2026, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025, and recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On March 5, 2026, the Company posted an updated corporate presentation on its website at www.invivyd.com. A copy of the presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated March 5, 2026

99.2

Corporate Presentation, dated March 5, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVIVYD, INC.

Date: March 5, 2026

By:

/s/ Jill Andersen

Jill Andersen

Chief Legal Officer and Corporate Secretary

2025
Q4

Q4 2025 Earnings

8-K SELL

Jan 8, 2026 · 100% conf.

AI Prediction SELL

1D

-2.20%

$1.62

Act: +3.16%

5D

-14.98%

$1.41

20D

-4.18%

$1.59

Price: $1.66 Prob +5D: 0% AUC: 1.000
0001193125-26-006997

8-K

false 0001832038 0001832038 2026-01-08 2026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2026

Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter)

Delaware

001-40703

85-1403134

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

209 Church Street New Haven, CT

06510

(Address of Principal Executive Offices)

(Zip Code) Registrant’s telephone number, including area code: (781) 819-0080 Not applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

IVVD

The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 8, 2026, Invivyd, Inc. (the “Company”) issued a press release entitled “Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights” (the “Press Release”), which included the Company’s estimated fourth quarter 2025 PEMGARDA® (pemivibart) net product revenue and cash and cash equivalents as of December 31, 2025. The amounts included in the Press Release are preliminary and are subject to change upon completion of the Company’s financial closing controls and procedures for the quarter and year ended December 31, 2025, and finalization of the Company’s financial statements. The preliminary financial data included in the Press Release have been prepared by, and are the responsibility of, the Company’s management. These preliminary estimates have not been audited by the Company’s independent registered public accounting firm. Additional information and disclosures would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 2.02.

Item 8.01 Other Events.

On January 8, 2026, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01. On January 8, 2026, the Company posted an updated corporate presentation on its website at www.invivyd.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference in this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated January 8, 2026

99.2

Corporate Presentation, dated January 8, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVIVYD, INC.

Date: January 8, 2026

By:

/s/ Jill Andersen

Jill Andersen

Chief Legal Officer and Corporate Secretary

2025
Q3

Q3 2025 Earnings

8-K

Nov 6, 2025

0001193125-25-268057

8-K

false 0001832038 0001832038 2025-11-06 2025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2025

Invivyd, Inc. (Exact Name of Registrant as Specified in its Charter)

Delaware

001-40703

85-1403134

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

209 Church Street

New Haven, CT

06510

(Address of Principal Executive Offices)

(Zip Code) Registrant’s telephone number, including area code: (781) 819-0080 Not applicable (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

IVVD

The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 6, 2025, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025, and recent business highlights. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On November 6, 2025, the Company posted an updated corporate presentation on its website at www.invivyd.com. A copy of the presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release, dated November 6, 2025

99.2

Corporate Presentation, dated November 6, 2025

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVIVYD, INC.

Date: November 6, 2025

By:

/s/ Jill Andersen

Jill Andersen

Chief Legal Officer and Corporate Secretary

Share on Social Networks: